Ilika plc appoints Dr. Louise Turner as VP Product Development

Ilika plc

Ilika Plc (LON:IKA), a pioneer in solid-state battery technology, today provided an update on senior appointments, a notice of conversion of preference shares, total voting rights, and an update to staff share option awards.

VP Product Development

With effect from 1 September 2023, Ilika has appointed Dr. Louise Turner to the role of VP Product Development. Promoted from her current position as Technical Director, Louise has demonstrated her skills in overseeing both the scientific development and scale-up activities of the Stereax® product and can draw on both her Doctorate in Chemistry and MBA in Business & Technology to further the Ilika story.

Dr. Louise Turner Ilika VP

Louise will take over line management responsibility for Ilika’s Stereax and Goliath product development programmes from Robin Bell. Robin will continue to work with and support the Company in an advisory capacity as New Product Introduction Director where he will continue supporting each product in its journey to market.

Ilika’s CEO Graeme Purdy, stated: “We are delighted to have the opportunity to promote such a capable leader and scientist as Louise to the senior management team. Louise will build on the product development and commercialisation work that she has delivered with the Stereax team to the wider business helping to enact the same scale up and delivery in the Goliath product roadmaps. We look forward to continuing our relationship with Robin in his new technical consulting role.”

Conversion of preference shares

Ilika announces that following receipt of conversion notices in relation to 426,300 convertible preferred Ordinary Shares of one penny each, it has today issued 426,300 Ordinary Shares. Accordingly, the Company has applied to the London Stock Exchange for 426,300 Ordinary Shares to be admitted to trading on AIM. It is expected that Admission will occur at 8:00 a.m. on 19 June 2023.

Total Voting Rights

Following Admission, the Company’s issued share capital will comprise 158,900,667 Ordinary Shares and that number may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure Guidance and Transparency Rules. The Company does not hold any shares in treasury.  

Award of share options update

The Company also announces that as part of the Company’s EMI option scheme, in addition to the 802,248 options granted over ordinary shares of one penny each in the Company (“Ordinary Shares”) on 1 March 2023, the Company awarded an additional 350,138 market value options to employees on 1 March 2023. Therefore, an aggregate of 1,572,140 options over Ordinary Shares had been granted to employees under the EMI option scheme on 1 March 2023, representing 0.99% of issued share capital.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Ilika plc reaches a commercial turning point as new markets emerge for Stereax and Goliath (video)

Dr Tom McColm of Morphose Capital Partners explains why the company may be approaching an important commercial inflection point.

Ilika plc: Stereax Revenue Arrives as Goliath Draws Defence Interest (video)

Ilika plc CEO Graeme Purdy outlines how Stereax has started generating product-related revenue, why M300 battery deliveries remain on track and how Goliath’s 10Ah prototype is opening new opportunities in defence and sovereign battery supply.

Ilika builds commercial momentum across Stereax and Goliath batteries

Ilika Plc reports annual results for the year ended 30 April 2026, highlighting progress on its Stereax medical battery line and Goliath large-format batteries for EV, defence and consumer applications. The company began Stereax production and deliveries, shipped larger Goliath prototypes, secured further grant funding and raised £5 million post-period to accelerate commercialisation.

Defence demand puts specialist battery technology in focus

Defence applications are increasing the need for specialist batteries that can deliver reliable power in demanding operating conditions.

Battery & Energy Storage Tech Europe 2026 targets the next phase of industrial growth

Battery & Energy Storage Tech Europe 2026 will focus on financing, deployment, manufacturing, recycling and regulation across Europe’s battery market.

Ilika moves Goliath cells into independent commercial testing

Ilika has moved its UK-made Goliath cells into independent testing as it targets commercial opportunities in automotive, defence and e-bike markets.

Search